AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all previous Listings of Claims.

Listing of Claims:

What is claimed is:

- 1. (Original) A process for preparing tetrahydrogeranylacetone, comprising:
- I. an aldol condensation of citral with acetone in the presence of aqueous alkali comprising at least one alkali metal hydroxide to form a condensate comprising pseudoionone and
 - II. a hydrogenation of the condensate.
- 2. (Original) The process according to claim 1, wherein steps I. and II. are carried out separately and successively.
 - 3. (Previously Presented) The process according to claim 1, wherein, continuously,
- a. citral, an excess of acetone and aqueous alkali are mixed at a temperature in the range from 10 to 120°C to give a homogeneous solution,
- b. subsequently, the homogeneous reaction mixture is passed in liquid form, with prevention of backmixing, at a temperature which is from 10 to 120°C above the boiling point of acetone, under a pressure which is from 10⁶ to 10⁷ Pa above the corresponding vapor pressure, but at least corresponds to the autogenous pressure of the reaction mixture, through a reactor which enables a residence time of from 2 to 300 minutes,
 - c. the reaction mixture is cooled under decompression,
- d. excess acetone is removed from the reaction mixture in countercurrent using steam.
 - e. the thus obtained crude product is purified using a rectification column and then
 - f. the thus obtained pseudoionone is hydrogenated to tetrahydrogeranylacetone.

Response to November 5, 2007 Office Action

4. (Previously Presented) The process according to claim 1, wherein the homogeneous solution of citral, acetone and aqueous alkali is prepared by removing the undissolved proportion of the aqueous alkali from the homogeneous mixture before the reaction.

- 5. (Previously Presented) The process according to claim 1, wherein acetone is added in a from 5- to 50-fold molar excess by removing the unconverted proportion downstream from the reaction zone at a pressure of from 10^7 to $5 \cdot 10^8$ mPa_{abs}, and feeding the fresh acetone back to the synthesis.
- 6. (Previously Presented) The process according to claim 1, wherein the reaction temperature at a given residence time is selected in such a way that the conversion of citral is from 60 to 98%, and the unconverted citral is removed and recycled into the reaction.
- 7. (Previously Presented) The process according to claim 1, wherein the water content of the acetone used for the reaction is between 1 and 15% by weight.
- 8. (Previously Presented) The process according to claim 1, wherein the concentration of the alkali metal hydroxide used for the reaction in the aqueous alkali is between 0.005 and 50% by weight.
- 9. (Previously Presented) The process according to claim 1, wherein the acetone used consists substantially of excess acetone, removed after the reaction, having a water content of from 1 to 15% by weight, to which either anhydrous or hydrous acetone having a water content of from 1 to 15% by weight may be added.
- 10. (Previously Presented) The process according to claim 1, wherein the water content of the acetone is adjusted by using a stripping column to remove the acetone from the reaction mixture, said stripping column being filled with commercial, structured packing elements, and irrigating it with an amount of from 10 to 90% of the acetone removed.

Response to November 5, 2007 Office Action

11. (Previously Presented) The process according to claim 1, wherein the byproducts present in the crude product comprising pseudoionone are removed and converted to acetone by action of a base in the presence of water.

- 12. (Previously Presented) The process according to claim 1, wherein the hydrogenation is carried out in liquid phase over suspended particles of a catalyst which is capable of preferentially hydrogenating carbon-carbon double bonds over carbon-oxygen double bonds, in the presence of a hydrogenous gas.
- 13. (Previously Presented) The process according to claim 1, wherein hydrogenation is effected using a catalyst whose active component comprises palladium.
- 14. (Previously Presented) The process according to claim 1, wherein the hydrogenation is carried out in an apparatus which inhibits the transport of the catalyst particles.
- 15. (Original) The process according to claim 14, wherein the apparatus inhibiting catalyst transport which is used is a knit, a bed, an open-cell foam structure or a packing element.
- 16. (Previously Presented) The process according to claim 14, wherein an apparatus inhibiting the transport of the catalyst particles is used which has orifices or channels whose hydraulic diameter is from 2 to 2000 times the average diameter of the catalyst particles.
- 17. (Previously Presented) The process according to claim 1, wherein the product of the hydrogenation is continuously removed from the catalyst suspension using a crossflow filter.
- 18. (Previously Presented) The process according to claim 1, wherein catalyst particles having a diameter of from 0.0001 to 2 mm are used in the hydrogenation.

Response to November 5, 2007 Office Action

19. (Previously Presented) The process according to claim 10, wherein the liquid phase and the hydrogenous gas are conducted through the apparatus inhibiting the transport of the catalyst particles at a superficial velocity of more than 100 m³/m²h.

- 20. (Previously Presented) The process according to claim 1, wherein the liquid phase in the hydrogenation comprises at least 80% by weight of hexahydropseudoionone.
- 21. (Previously Presented) The process according to claim 1, wherein the reaction pressure in the hydrogenation is selected in the range from 1 to 100 bar_{abs}.
- 22. (Previously Presented) The process according to claim 1, wherein the reaction temperature in the hydrogenation is selected in the range from 20 to 120°C.
- 23. (Currently Amended) The use of process for preparing tetrahydrogeranylacetone obtained according to claim 1 for preparing phytol, isophytol, tocopherol and/or tocopherol derivatives.
 - 24. (Currently Amended) A process for preparing tocopherols and/or tocopherol derivatives, comprising
 - the preparation of tetrahydrogeranylacetone according to any of claim 1, a)
 - an aldol condensation of citral with acetone in the presence of aqueous alkali comprising at least one alkali metal hydroxide to form a condensate comprising pseudoionone, and
 - a hydrogenation of the condensate, Π .
- a reaction of the thus obtained tetrahydrogeranylacetone with a vinylmagnesium b) halide to give 3,7,11-trimethyl-1-dodecen-3-ol3,7,11-trimethyl-1-dodecen-3-ol,
- a reaction of thus obtained 3,7,11-trimethyl-1-dodecen-3-ol with diketene or ethyl c) acetoacetate to give the corresponding esterester,
- a rearrangement of the thus obtained ester by Carroll reaction to give 6,10,14d) trimethyl-5-pentadecen-2-one,

Application No. 10/596,335 Amendment dated February 5, 2008

Response to November 5, 2007 Office Action

e) a reaction of thus obtained 6,10,14-trimethyl-5-pentadecen-2-one with hydrogen to give 6,10,14-trimethyl-pentadecan-2-one,

Docket No.: 12810-00274-US1

- f) a reaction of thus obtained 6,10,14-trimethyl-pentadecan-2-one with a vinylmagnesium halide to give 3,7,11,15-tetramethyl-1-hexadecen-3-ol and 3,7,11,15-tetramethyl-1-hexadecen-3-ol,
 - g) a reaction of 3,7,11,15-tetramethyl-1-hexadecen-3-ol to give tocopherol and
 - h) if appropriate, an acetylation of the thus obtained tocopherol.
- 25. (Currently Amended) A process for preparing tocopherols and/or tocopherol derivatives, comprising
- a) an aldol condensation of citral with acetone in the presence of a basic substance to form a condensate comprising pseudoionone,
- b) a hydrogenation of the pseudoionone present in the condensate to give 6,10-dimethyl-2-undecanone,
- c) a reaction of thus obtained 6,10-dimethyl-2-undecanone with acetylene in the presence of a basic compound to give 3,7,11-trimethyl-1-dodecyn-3-ol,
- d) a reaction of thus obtained 3,7,11-trimethyl-1-dodecyn-3-ol with hydrogen in the presence of a catalyst comprising palladium, silver and/or bismuth and carbon monoxide to give 3,7,11-trimethyl-1-dodecen-3-ol,
- e) a reaction of thus obtained 3,7,11-trimethyl-1-dodecen-3-ol with diketene or ethyl acetoacetate to give the corresponding ester,
- f) a rearrangement of the thus obtained ester to give 6,10,14-trimethyl-5-pentadecen-2-one by Carroll reaction,
- g) a reaction of thus obtained 6,10,14-trimethyl-5-pentadecen-2-one with hydrogen to give 6,10,14-trimethylpentadecan-2-one,
- h) a reaction of thus obtained 6,10,14-trimethylpentadecan-2-one with acetylene in the presence of a base to give 3,7,11,15-tetramethyl-1-hexadecyn-3-ol,
- i) a reaction of thus obtained 3,7,11,15-tetramethyl-1-hexadecin-3-ol with hydrogen in the presence of a catalyst comprising palladium, silver and/or bismuth and carbon monoxide to give 3,7,11,15-tetramethyl-1-hexadecen-3-ol and 3,7,11,15-tetramethyl-1-hexadecen-3-ol.

Application No. 10/596,335 Amendment dated February 5, 2008 Response to November 5, 2007 Office Action

j) a reaction of 3,7,11,15-tetramethyl-1-hexadecen-3-ol to give tocopherol and/or

Docket No.: 12810-00274-US1

tocopherol derivatives and

k) if appropriate, an acetylation of the thus obtained tocopherol.